CR20230245A - Moléculas de unión a gucy2c y sus usos - Google Patents
Moléculas de unión a gucy2c y sus usosInfo
- Publication number
- CR20230245A CR20230245A CR20230245A CR20230245A CR20230245A CR 20230245 A CR20230245 A CR 20230245A CR 20230245 A CR20230245 A CR 20230245A CR 20230245 A CR20230245 A CR 20230245A CR 20230245 A CR20230245 A CR 20230245A
- Authority
- CR
- Costa Rica
- Prior art keywords
- gucy2c
- binding molecules
- chimeric antigen
- antigen receptors
- cells
- Prior art date
Links
- 101150017853 GUCY2C gene Proteins 0.000 title 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102100022662 Guanylyl cyclase C Human genes 0.000 abstract 1
- 101000899808 Homo sapiens Guanylyl cyclase C Proteins 0.000 abstract 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000012642 immune effector Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464464—GTPases, e.g. Ras or Rho
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/50—Colon
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y406/00—Phosphorus-oxygen lyases (4.6)
- C12Y406/01—Phosphorus-oxygen lyases (4.6.1)
- C12Y406/01002—Guanylate cyclase (4.6.1.2)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se proporciona anticuerpos de un solo dominio que se unen a GUCY2C y receptores de antígenos quiméricos que los comprenden. Además se proporcionan células efectoras inmunitarias modificadas (tales como linfocitos T) que comprenden los receptores de antígenos quiméricos. También se proporcionan composiciones farmacéuticas, kits y métodos para tratar una enfermedad o trastorno.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020137164 | 2020-12-17 | ||
PCT/CN2021/138845 WO2022127871A1 (en) | 2020-12-17 | 2021-12-16 | Gucy2c binding molecules and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20230245A true CR20230245A (es) | 2023-09-01 |
Family
ID=82060074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20230245A CR20230245A (es) | 2020-12-17 | 2021-12-16 | Moléculas de unión a gucy2c y sus usos |
Country Status (15)
Country | Link |
---|---|
US (1) | US20240059794A1 (es) |
EP (1) | EP4263615A1 (es) |
JP (1) | JP2023554467A (es) |
KR (1) | KR20230131183A (es) |
CN (2) | CN116917329A (es) |
AU (1) | AU2021404641A1 (es) |
BR (1) | BR112023011658A2 (es) |
CA (1) | CA3205007A1 (es) |
CL (1) | CL2023001665A1 (es) |
CO (1) | CO2023009279A2 (es) |
CR (1) | CR20230245A (es) |
EC (1) | ECSP23053774A (es) |
IL (1) | IL303610A (es) |
MX (1) | MX2023006969A (es) |
WO (1) | WO2022127871A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024027815A1 (zh) * | 2022-08-05 | 2024-02-08 | 江苏恒瑞医药股份有限公司 | 特异性结合gucy2c和cd3的抗原结合分子及其医药用途 |
CN115894697B (zh) * | 2022-12-09 | 2023-08-29 | 华道(上海)生物医药有限公司 | 一种抗鸟苷酸环化酶2c的纳米抗体及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9156915B2 (en) * | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
MX362020B (es) * | 2012-04-27 | 2019-01-04 | Millennium Pharm Inc | Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc. |
CA3087135A1 (en) * | 2018-01-04 | 2019-07-11 | Shanghai Lumosa Therapeutics Co., Ltd. | Single-domain antibody-cytosine deaminase fusion proteins |
TWI803637B (zh) * | 2018-05-23 | 2023-06-01 | 美商輝瑞大藥廠 | 特異性針對gucy2c之抗體及其用途 |
-
2021
- 2021-12-16 KR KR1020237020647A patent/KR20230131183A/ko unknown
- 2021-12-16 CR CR20230245A patent/CR20230245A/es unknown
- 2021-12-16 CA CA3205007A patent/CA3205007A1/en active Pending
- 2021-12-16 AU AU2021404641A patent/AU2021404641A1/en active Pending
- 2021-12-16 WO PCT/CN2021/138845 patent/WO2022127871A1/en active Application Filing
- 2021-12-16 JP JP2023537253A patent/JP2023554467A/ja active Pending
- 2021-12-16 IL IL303610A patent/IL303610A/en unknown
- 2021-12-16 CN CN202180093966.2A patent/CN116917329A/zh active Pending
- 2021-12-16 BR BR112023011658A patent/BR112023011658A2/pt unknown
- 2021-12-16 EP EP21905797.3A patent/EP4263615A1/en active Pending
- 2021-12-16 US US18/265,779 patent/US20240059794A1/en active Pending
- 2021-12-16 MX MX2023006969A patent/MX2023006969A/es unknown
- 2021-12-16 CN CN202311602780.2A patent/CN118146381A/zh active Pending
-
2023
- 2023-06-08 CL CL2023001665A patent/CL2023001665A1/es unknown
- 2023-07-13 CO CONC2023/0009279A patent/CO2023009279A2/es unknown
- 2023-07-17 EC ECSENADI202353774A patent/ECSP23053774A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN118146381A (zh) | 2024-06-07 |
CL2023001665A1 (es) | 2024-01-12 |
EP4263615A1 (en) | 2023-10-25 |
WO2022127871A1 (en) | 2022-06-23 |
MX2023006969A (es) | 2023-08-25 |
AU2021404641A1 (en) | 2023-06-29 |
CN116917329A (zh) | 2023-10-20 |
BR112023011658A2 (pt) | 2023-10-17 |
US20240059794A1 (en) | 2024-02-22 |
CA3205007A1 (en) | 2022-06-23 |
CO2023009279A2 (es) | 2023-07-21 |
JP2023554467A (ja) | 2023-12-27 |
KR20230131183A (ko) | 2023-09-12 |
IL303610A (en) | 2023-08-01 |
ECSP23053774A (es) | 2023-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018500295A1 (en) | Chimeric antigen receptors based on single-domain antibodies and methods of use thereof | |
AU2019415848A8 (en) | Claudin18.2 binding moieties and uses thereof | |
ZA202206437B (en) | Claudin18.2 binding moieties and uses thereof | |
MX2022000325A (es) | Anticuerpos dirigidos contra dll3 y usos de los mismos. | |
CR20230245A (es) | Moléculas de unión a gucy2c y sus usos | |
MY194997A (en) | Anti-ccr7 antibody drug conjugates | |
MY150246A (en) | Alpha 5 - beta 1 antibodies and their uses | |
WO2019060750A3 (en) | A33 antibody compositions and methods of using the same in radioimmunotherapy | |
WO2022031884A3 (en) | Il2rg binding molecules and methods of use | |
WO2022031940A3 (en) | Il28ra binding molecules and methods of use | |
MX2021006362A (es) | Anticuerpos de dominio simple contra cll-1. | |
MX2010001237A (es) | Nuevos anticuerpos. | |
WO2022051591A3 (en) | Nectin-4 antibodies and uses thereof | |
WO2022032006A9 (en) | Il2rb binding molecules and methods of use | |
MX2021009975A (es) | Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer. | |
MX2023009022A (es) | Anticuerpos multiespecificos con especificidad para ror1 y cd3. | |
WO2021231651A3 (en) | Sars-cov2 neutralizing single domain antibody constructs | |
MX2023010499A (es) | Anticuerpos heterodimericos que se unen a cd3 y cldn6. | |
WO2022032003A3 (en) | Anti-claudin 18.2 antibodies and uses thereof | |
MX2022016322A (es) | Anticuerpos de alta afinidad dirigidos a tau fosforilada en la serina 413. | |
WO2021263167A3 (en) | Il-10 muteins and fusion proteins thereof | |
WO2020014505A3 (en) | COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS | |
MX2009008754A (es) | Anticuerpos novedosos contra igf-1r. | |
MX2021008453A (es) | Formulaciones de anticuerpos que se unen a cd137 humano y usos de los mismos. | |
EA202191821A1 (ru) | Группы, связывающие клаудин 18.2, и их использование |